A real world study assessing the association between molecular alterations with hyperprogression in lung cancer patients treated with immune checkpoint inhibitors
Latest Information Update: 24 Jun 2020
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
Most Recent Events
- 24 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology